Childhood cancers trials in Italy

In Italy 205 Also abroad 2483

205 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Bologna, Ravenna
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
No phaseNot yet taking people in Italy
Healthcare Providers' Attitudes Toward Oncology Patients With Mental Disorders
Where
Aviano, Bari, Meldola, Padova, Rionero in Vulture
People
1,000
Run by
Istituto Oncologico Veneto IRCCS
See details and how to joinNCT07748221
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Alexandria, Bari, Bergamo, Bologna, Brescia, Candiolo, Florence, Genoa, Meldola, Milan, Modena, Monza, Naples, Palermo, Pavia, Perugia, Pesaro, Pisa, Reggio Calabria, Reggio Emilia, Rimini, Rome, Turin, Udine
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 1Taking people
Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
Where
Rome
Age
1 year to 35 years
People
24
Run by
Bambino Gesù Hospital and Research Institute
See details and how to joinNCT06080191
Phase 2/3Not yet taking people in Italy
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Where
Roma
Age
3 months to 25 years
People
1,000 worldwide
Run by
Bambino Gesù Hospital and Research Institute
See details and how to joinNCT07297914 · EU 2025-522052-13-00
Phase 3Completed
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Where
Milan, Pavia, Roma, Torino
People
115 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT03394365 · EU 2024-516622-57-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Cosenza, Florence, Genoa, Monza, Naples, Padova, Palermo, Parma, Pavia, Rome, Trieste, Turin, Verona
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00
No phaseTaking people
Prospective Multicenter Study of the Genomic, Transcriptomic, and Biological Profile of Patients With Neuroblastoma
Where
Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Catanzaro, Cosenza, Ferrara, Florence, Genova, Milan, Modena, Naples, Padova, Palermo, Parma, Pavia, Perugia, Pescara, Pisa, Reggio Calabria, Rimini, Roma, San Giovanni Rotondo, Sassari, Siena, Torino, Trieste, Verona
Age
0 days to 31 years
People
200
Run by
Istituto Giannina Gaslini
See details and how to joinNCT07881172
Phase 1/2Taking people
CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults
Where
Bergamo, Monza
Age
6 months to 75 years
People
18
Run by
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
See details and how to joinNCT07877610
Phase 1/2Taking people
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Where
Bergamo, Bologna, Meldola, Monza, Naples, Rome
Age
12 years and over
People
255 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00
Phase 1/2Taking people
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Where
Alessandria, Bologna, Milan
Age
12 years and over
People
161 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Bologna, Meldola, Milan, Rome, Vicenza
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1Taking people
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Where
Monza, Rome
Age
0 years to 21 years
People
20 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00
No phaseTaking people
MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms
Where
Milan
Age
16 years and over
People
1,190
Run by
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT07863466
Phase 1/2Not yet taking people in Italy
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
Where
Genoa, Monza, Rome
Age
Up to 64 years
People
22 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522019-40-00
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Alexandria, Ancona, Bari, Bergamo, Candiolo, Genoa, Messina, Milan, Modena, Padova, Rome, San Giovanni Rotondo, Siena, Trento
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 1/2Taking people
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Where
Milan, Rome, Turin
Age
1 month to 17 years
People
50 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00
Phase 1Taking people
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Where
Rome
Age
6 months to 17 years
People
18 worldwide
Run by
AbbVie
See details and how to joinNCT07306832
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Candiolo, Milan, Naples, Rome, Rozzano
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1Taking people
GD2-CAR T Cells for Pediatric Brain Tumours
Where
Roma
Age
6 months to 30 years
People
54
Run by
Bambino Gesù Hospital and Research Institute
See details and how to joinNCT05298995
Phase 1/2Taking people
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Where
Milan
Age
Up to 25 years
People
75 worldwide
Run by
Turning Point Therapeutics, Inc.
See details and how to joinNCT04094610 · EU 2023-506464-14-00
Phase 1/2Taking people
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Where
Ancona, Bari, Milan, Padova, Ravenna, Rome
Age
12 years and over
People
359 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00
Phase 2Taking people
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Where
Bologna, Catania, Genova, Monza, Naples, Padova, Palermo, Pavia, Rome, Torino, Trieste
Age
1 year to 17 years
People
100 worldwide
Run by
Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00
Phase 3Taking people
Randomized study to protect from radiation iatrogenic hypothyroidism patients with medulloblastoma (any stage, any biological risk) and pediatric patients with Hodgkin lymphoma and non-Hodgkin lymphoma needing radiation therapy on thyroid site - WINHYPO 2021
Where
Milan
People
65
Run by
Fondazione IRCCS Istituto Nazionale Dei Tumori
See details and how to join2024-512642-42-00
Phase 2Taking people
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
Where
Milan, Rome
People
1,500 worldwide
Run by
Kite, A Gilead Company
See details and how to joinNCT05041309 · EU 2023-507041-28-00